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Abstract
TNF-α, a proinflammatory cytokine, inhibits osteo-
blast differentiation under diverse inflammatory con-
ditions; however, the underlying mechanisms in terms 
of the TNF-α signaling pathway remain unclear. In this 
study, we examined the role of Msx2 in TNF-α-medi-
ated inhibition of alkaline phosphatase (ALP) ex-
pression and the signaling pathways involved. TNF-α 
down-regulated ALP expression induced by bone mor-
phogenetic protein 2 (BMP2) in C2C12 and Runx2-/- cal-
varial cells. Over-expression of Msx2 suppressed 
BMP2-induced ALP expression. Furthermore, TNF-α 
induced Msx2 expression, and the knockdown of Msx2 
by small interfering RNAs rescued ALP expression, 
which was inhibited by TNF-α. TNF-α activated the 
NF-κB and the JNK pathways. Inhibition of NF-κB or 
JNK activation reduced the inhibitory effect of TNF-α 
on ALP expression, whereas TNF-α-induced Msx2 ex-
pression was only suppressed by the inhibition of the 
NF-κB pathway. Taken together, these results indicate 
that Msx2 mediates the inhibitory action of TNF-α on 
BMP2-regulated osteoblast differentiation and that the 
TNF-α-activated NF-κB pathway is responsible for 
Msx2 induction.
Keywords: alkaline phosphatase; bone morphoge-
netic protein 2; cell differentiation; Msx2 protein; 
NF-κB; osteoblasts; tumor necrosis factor-α
Introduction
TNF-α is a proinflammatory cytokine that plays an 
important role in various physiological and patho-
logical processes including cell death, growth, 
differentiation and inflammation (Chen and Goeddel, 
2002; Wajant et al., 2003). In bone tissue, there is 
a long-standing interest in the role of TNF-α 
because of its association with osteoporosis and 
rheumatoid arthritis. TNF-α is overproduced in the 
bone marrow of postmenopausal osteoporosis 
patients and within the synovium of rheumatoid 
arthritis lesions, contributing to both systemic and 
local bone loss (Feldmann et al., 1996; Pfeilschifter 
et al., 2002). TNF-α increases bone resorption by 
promoting osteoclast differentiation and activation 
(Nanes, 2003; Boyce et al., 2005). In addition, 
TNF-α decreases osteoblastic bone formation 
through the promotion of osteoblast apoptosis, the 
inhibition of osteoblast differentiation and the 
suppression of the matrix protein expression such 
as osteocalcin by mature osteoblasts (Kuno et al., 
1994; Kitajima et al., 1996; Nakase et al., 1997; 
Gilbert et al., 2000, 2002). To date, the most 
important mechanism of TNF-mediated inhibition of 
osteoblast differentiation is the regulation of 
Runx2, a critical transcription factor for osteoblast 
differentiation. TNF-α decreases both the mRNA 
and protein levels of Runx2 via the suppression of 
transcription, destabilization of mRNA, and enhan-
ced degradation of Runx2 protein (Gilbert et al., 
2002; Kaneki et al., 2006). Although the inhibitory 
roles of TNF-α in osteoblast differentiation have 
been described, the detailed TNF-α signaling 
pathways involved remain unclear.
    Msx2 belongs to the homeobox transcription 
factor family, and Msx2 is involved in cranial bone 
development (Ferguson, 1994; Alappat et al., 
2003). Msx2-deficient mice show defects in cranial 
bone formation, whereas transgenic mice over-ex-
pressing wild type Msx2 exhibit an overall increase 
in bone volume (Satokata et al., 2000; Cheng et 
al., 2008). In humans, haploinsufficiency of MSX2 
causes parietal foramina; however, its gain-of-func-
tion mutation leads to craniosynostosis syndrome 
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Figure 1. TNF-α suppresses BMP2-induced ALP expression in Runx2-/- cells. (A, B) C2C12 cells were incubated in DMEM supplemented with 5% FBS 
for 24 h in the presence of the indicated reagents. Runx2+/+ and Runx2-/- cells were incubated in α-MEM supplemented with 10% FBS, 10 mM 
β-glycerophosphate and 50 μg/ml ascorbic acid for 48 h in the presence of the indicated reagents. Then, ALP staining (A) or RT-PCR (B) was performed. 
(C) To block new protein synthesis, C2C12 cells were treated with BMP2 and/or TNF-α in the presence of cycloheximide (CHX, 10 μg/ml) for 24 h. The 
concentrations of TNF-α and BMP2 were 10 ng/ml and 100 ng/ml, respectively, or as otherwise indicated. *, In Runx2-/- cells, the RT-PCR products of the 
ALP gene were obtained by carrying out the amplification step for five more cycles than in C2C12 and Runx2+/+ cells.
(Jabs et al., 1993; Wilkie et al., 2000). Despite 
these in vivo phenotypes, the exact function of 
Msx2 in osteoblast differentiation remains contro-
versial. Several reports have shown that Msx2 
promotes osteogenic differentiation but suppresses 
adipogenic differentiation (Cheng et al., 2003; 
Ichida et al., 2004). Alternatively, there have been 
several lines of opposing evidence showing that 
Msx2 suppresses the expression of bone marker 
genes, including Runx2, alkaline phosphatase 
(ALP), and osteocalcin (Shirakabe et al., 2001; 
Hassan et al., 2004; Kim et al., 2004). Thus, the 
role of Msx2 in osteoblast differentiation needs to 
be further clarified.
    Recently, we showed that TNF-α promotes 
MSX2 expression in human vascular smooth 
muscle cells (Lee et al., 2010). Considering that 
TNF-α suppresses ALP activity (Gilbert et al., 2002) 
and that Msx2 inhibits ALP expression (Kim et al., 
2004), we hypothesized that Msx2 may be a new 
target molecule that mediates the inhibitory action 
of TNF-α on osteoblast differentiation. Therefore, we 
examined the role of Msx2 in the TNF-α-mediated 
inhibition of ALP expression and the underlying 
regulatory mechanism in terms of the signal 
transduction pathway. In the present study, we 
showed that TNF-α induces Msx2 expression in 
C2C12 cells through NF-κB activation, which in 
turn inhibits bone morphogenetic protein 2 
(BMP2)-induced expression of ALP.
Results
As an in vitro model system, C2C12, a murine 
mesenchymal precursor cell line, which can 
differentiate into several cell types such as 
myocytes, adipocytes, and osteoblasts, was used 
in this study (Lee et al., 2000). We first examined 
the effect of TNF-α on BMP2-induced osteoblast 
differentiation. C2C12 cells were osteogenically 
induced by BMP2 (100 ng/ml) treatment for 24 h. 
Osteogenic induction was verified by cytochemical 
staining of ALP, an early osteogenic marker. TNF-α 
inhibited BMP2-induced ALP activity in a 
dose-dependent manner (Figure 1A). TNF-α almost 
completely suppressed ALP activity at 10 ng/ml 
concentration. Consistent with ALP staining data, 
induction of ALP mRNA expression by BMP2 was 
also blocked by TNF-α (Figure 1B). 
    Next, we examined the effect of TNF-α in 
Runx2-/- calvarial preosteoblast cells to analyze the 
involvement of target genes other than Runx2. 
Expectedly, BMP2 weakly induced ALP activity in 
Runx2-/- cells compared to C2C12 cells (Figure 
1A). TNF-α also exerted an inhibitory effect on 
BMP2-induced ALP activity and mRNA expression 
in Runx2-/- cells (Figures 1A and 1B). The absence 
of Runx2 transcripts in Runx2-/- cells was con-
firmed by RT-PCR (Figure 1B). As a positive 
control, we used calvarial cells from wild type ICR 
mice. TNF-α also showed inhibitory effect on 
BMP2-induced ALP expression in Runx2+/+ cells 
but to a lesser degree compared to that in C2C12 
cells and Runx2-/- cells (Figure 1B). Next, we 
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Figure 2. Expression of Msx2 is induced by TNF-α. (A) Over-expressed Msx2 inhibited BMP2-induced ALP expression. C2C12 cells were transiently 
transfected with pcDNA or the Msx2 expression vector and incubated in the presence of BMP2 for 24 h. RT-PCR was then performed. (B) C2C12 cells 
were incubated in the presence of the indicated reagents for 24 or 48 h. RT-PCR (left panel) or western blot analysis (right panel, nuclear extracts of 24 h 
samples) was performed to detect Msx2 induction. Histone H3 was used as a loading control. (C) Runx2+/+ and Runx2-/- cells were incubated in the pres-
ence of the indicated reagents for 24 h, and RT-PCR was performed. (D) Runx2 did not exert any effect on TNF-α-induced Msx2 expression. Runx2-/- 
cells were transiently transfected with pcDNA or the Runx2 expression vector and incubated in the presence of TNF-α for 24 h. RT-PCR was then 
performed.
observed the mRNA level of Smurf1, an E3 
ubiquitin ligase, because it is involved in TNF-α-in-
duced degradation of Runx2 and BMP signaling 
proteins (Kaneki et al., 2006; Guo et al., 2008). As 
previously reported, TNF-α stimulated the expre-
ssion of Smurf1 in C2C12 and Runx2+/+ cells 
(Figure 1B); however, Smurf1 was not expressed 
in Runx2-/- cells, indicating that new target 
molecules other than Runx2 and Smurf1 may be 
involved in TNF-α-mediated inhibition of ALP 
activity in Runx2-/- cells.
    To examine whether TNF-α-mediated inhibition 
of ALP expression requires new protein synthesis, 
we treated C2C12 cells with TNF-α and/or BMP2 
in the presence of cycloheximide, a protein 
synthesis inhibitor, and then examined the expre-
ssion of ALP mRNA. As shown in Figure 1C, 
TNF-α did not exert a significant inhibitory effect on 
ALP expression in the presence of cycloheximide, 
indicating that the suppressive activity of TNF-α on 
BMP2-induced ALP expression requires new 
protein synthesis.
    Before we examined the involvement of Msx2 in 
TNF-α-mediated ALP suppression, we first analy-
zed the effect of Msx2 on BMP2-induced ALP 
expression in our culture system. C2C12 cells 
were transiently transfected with pcDNA or an 
Msx2 expression vector and incubated with BMP2 
for 24 h. As previously reported (Kim et al., 2004), 
BMP2-induced ALP expression was partially 
suppressed by Msx2 over-expression (Figure 2A). 
Next, we examined whether TNF-α regulates the 
expression of Msx2 in C2C12 cells. RT-PCR and 
immunoblot data demonstrated that TNF-α signi-
ficantly up-regulated Msx2 expression at both the 
mRNA and protein level (Figure 2B, left and right 
panel); BMP2 alone did not increase Msx2 expre-
ssion significantly; however, TNF-α-induced Msx2 
expression was enhanced by BMP2. We also 
observed the effect of TNF-α on the expression of 
Msx2 in Runx2-/- cells. Similarly, TNF-α stimulated 
the expression of Msx2 in Runx2-/- cells as well as 
in Runx2+/+ cells (Figure 2C). Rescue of Runx2 
expression in Runx2-/- cells did not change the 
Msx2 response to TNF-α (Figure 2D). Overall, 
these data suggest that Msx2 is a possible new 
TNF-α target molecule.
    To further define the role of Msx2 in TNF-α-in-
hibited ALP expression, we examined the expre-
ssion levels of ALP after Msx2 knockdown by 
siRNA. The efficiency of Msx2 siRNA was verified 
by RT-PCR and immunoblot analysis (Figure 3). 
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Figure 3. TNF-α-inhibited ALP expression is rescued by the knockdown 
of Msx2. To induce the silencing of Msx2, C2C12 cells were transfected 
with siRNAs for Msx2 (si Msx2) or control siRNAs (si control) and further 
incubated in the presence of the indicated reagents for 24 h. Next, 
RT-PCR, immunoblot analysis and ALP staining were performed. Lamin 
B was used as a loading control.
Msx2 siRNA clearly suppressed both basal and 
TNF-α-induced Msx2 expression. Furthermore, 
RT-PCR and ALP staining results showed that ALP 
mRNA expression and activity that were suppre-
ssed by TNF-α were partially rescued by Msx2 
knockdown (Figure 3). These results indicate that 
TNF-α-induced Msx2 partially mediates the suppr-
essive action of TNF-α on ALP expression. 
    To define the link between the activation of the 
TNF receptor and Msx2 expression, we investi-
gated TNF receptor downstream signaling path-
ways. TNF-α mainly activates MAPKs and the 
NF-κB pathway (Chen and Goeddel, 2002; Wajant 
et al., 2003). First, we examined the involvement of 
the NF-κB pathway in TNF activity. Immunoblot 
data showed that treatment with TNF-α increased 
IκBα phosphorylation within 10 min of TNF-α 
addition (Figure 4A, upper panel). BAY-11-7082, an 
NF-κB inhibitor, was used to block NF-κB acti-
vation. At the concentration used in this study (10 
μM), BAY-11-7082 did not exhibit cytotoxicity or 
anti-proliferative activity (Figure 4B). RT-PCR and 
immunoblot data showed that BAY-11-7082 abro-
gated the induction of Msx2 expression by TNF-α 
(Figure 4A, middle panel). Consistent with the 
Msx2 results, TNF-α-inhibited ALP mRNA expression 
and activity were partially rescued by BAY-11-7082 
treatment (Figure 4A, middle and lower panel). To rule 
out the nonspecific effects of BAY-11-7082, we 
over-expressed dnIκBα(S32A/S36A) in C2C12 cells 
to prevent NF-κB activation. These mutations 
render the protein non-phosphorylatable and 
consequently not degradable, inhibiting nuclear 
translocation of NF-κB (Brockman et al., 1995). 
Over-expression of dnIκBα effectively blocked 
TNF-α-induced nuclear translocation of RelA, a 
NF-κB p65 subunit (Figure 4C, upper panel). 
RT-PCR and immunoblot results showed that 
TNF-α-induced Msx2 expression was abolished 
when NF-κB was sequestered in the cytoplasm by 
dnIκBα (Figure 4C). Taken together, these results 
demonstrate that NF-κB activation is required for 
Msx2 induction by TNF-α.
    We also examined the effect of JNK activation 
on Msx2 expression because it has been reported 
that TNF-α inhibits BMP-induced osteoblast differen-
tiation through JNK signaling (Mukai et al., 2007). 
TNF-α treatment increased the phosphorylation of 
JNK and its downstream target, c-Jun, within five 
min (Figure 5A). Although a previous report has 
shown that SP600125, a JNK inhibitor, promotes 
apoptosis in human leukemia cells (Moon et al., 
2009), it did not exert cytotoxic effects on C2C12 
cells at 10 μM concentration (Figure 5B). RT-PCR 
and immunoblot analyses revealed that Msx2 
induction by TNF-α was not affected by SP600125 
treatment. Apart from the effect on Msx2 expr-
ession, SP600125 partially rescued ALP mRNA 
expression that was suppressed by TNF-α (Figure 
5C). These results suggest that the JNK pathway 
is not involved in TNF-α-induced Msx2 expression, 
but the pathway acts in TNF-α-mediated suppr-
ession of ALP expression.
Discussion
Previous reports have demonstrated that TNF-α 
inhibits spontaneous and BMP-induced osteoblast 
differentiation (Nakase et al., 1997; Gilbert et al., 
2000). The major mechanistic findings of TNF-me-
diated osteoblast inhibition include suppression of 
Runx2 expression and diminution of BMP res-
ponses by reducing the levels of the BMP receptor 
and R-Smads (Gilbert et al., 2002; Kaneki et al., 
2006; Singhatanadgit et al., 2006; Guo et al., 
2008). Smurf1 promotes the proteasomal degra-
dation of Runx2, the BMP receptor, and R-Smads 
by inducing ubiquitination. Smurf1 is also known to 
mediate TNF-induced systemic bone loss (Kaneki 
et al., 2006; Guo et al., 2008). In this study, based 
on the observations that TNF-α inhibited BMP2-in-
duced ALP expression in Runx2-/- cells and that 
Smurf1 was not expressed in these cells, we 
deduced that molecules other than Runx2 and 
Smurf1 may also be involved in TNF-α-mediated 
suppression of osteoblast differentiation. Here, we 
present Msx2 as a novel target of TNF-α that 
mediates its inhibitory effect on ALP expression. 
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Figure 4. TNF-α induces Msx2 expression via NF-κB activation. (A) Inhibition of NF-κB activation by BAY-11-7082 (BAY, 10 μM) blocked TNF-α-induced 
Msx2 expression. C2C12 cells were treated with the indicated reagents for 10 min (upper panel) or for 24 h (middle and lower panels), and then immuno-
blotting, RT-PCR and ALP staining were performed. The levels of phospho-IκBα and total IκBα were examined using whole cell lysates whereas the 
Msx2 protein level was examined using nuclear extracts. (B) BAY-11-7082 did not exert any cytotoxic effects at a concentration of 10 μM. The cell cytotox-
icity/proliferation assay was performed using the CCK-8 reagent as described in Methods. Data represent the mean + SD of quadruplicates. *, P ＜ 0.01 
(Student's t-test) (C) Over-expression of dnIκBα suppressed TNF-α-induced Msx2 expression. C2C12 cells were transiently transfected with pcDNA or 
the dnIκBα expression vector and incubated in the presence of TNF-α for 24 h. Next, RT-PCR and immunoblot analyses were performed.
We provide several lines of evidence implicating 
Msx2 in TNF-α-mediated suppression of osteoblast 
differentiation: (i) TNF-α induced the expression of 
Msx2 in both C2C12 cells and Runx2-/- cells; (ii) 
over-expression of Msx2 suppressed BMP2-induced 
ALP expression; (iii) knockdown of Msx2 expre-
ssion by siRNA or blocking of Msx2 induction by 
the inhibition of NF-κB activation rescued ALP 
expression in the presence of TNF-α.
    As described above, the biological function of 
Msx2 in osteoblast differentiation is currently con-
troversial because studies have provided evidence 
of the role of Msx2 as both a negative or positive 
regulator (Komori, 2006). In this study, we aimed to 
define the role of Msx2 in the context of TNF-α-me-
diated inhibition of osteogenic differentiation. Our 
results showed that Msx2 plays a significant role in  
TNF-α-mediated inhibition of osteoblast differentia-
tion, implicating Msx2 as a negative regulator of 
osteogenic differentiation. Molecular genetic studies 
have shown that Msx2 is essential for normal 
suture closure and skull mineralization (Jabs et al., 
1993; Satokata et al., 2000; Wilkie et al., 2000; 
Cheng et al., 2008). Based on these in vivo 
phenotypes of Msx2 or MSX2 mutations, it has 
been thought that Msx2 acts as a positive regulator 
of osteoblast differentiation. A recent study, however, 
demonstrated that the Boston-type craniosy-
nostosis MSX2 mutation (P148H) is not a 
gain-of-function mutation but is, instead, a 
loss-of-function mutation (Yoon et al., 2008). Yoon 
and colleagues showed that during murine calva-
rial development, Msx2 expression is localized 
predominantly in the suture mesenchyme and 
suggested that the primary function of MSX2 in 
calvarial bone development is to induce cell 
proliferation and suture maintenance but not to 
promote osteoblast differentiation (Yoon et al., 
2008). In the cell culture system, the expression 
level of Msx2 in osteogenic lineage cells is 
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regulated according to the stages of differentiation 
and maturation. For example, the expression level 
of Msx2 is maximum at the proliferating stage and 
subsequently decreases during the maturation of 
osteoblasts (Hassan et al., 2009). Moreover, Msx2 
inhibits the function of key osteogenic regulators 
such as Runx2 and Dlx5 via protein-protein inte-
ractions and/or binding competition on DNA 
sequences, resulting in the suppression of the 
expression of the major osteogenic marker genes, 
ALP and osteocalcin (Zhang et al., 1997; 
Shirakabe et al., 2001; Hassan et al., 2004, 2006; 
Kim et al., 2004). In support of these reports, a 
recent study has also demonstrated that calvarial 
cells derived from Msx2-deficient mice are less 
proliferative and show a higher level of minerali-
zation and bone differentiation marker gene expre-
ssion than cells from wild type mice (Marijanovic ́ et 
al., 2009). In addition, it has been demonstrated 
that Msx2 acts as a molecular defense mechanism 
that prevents ossification of ligament and dermal 
fibroblasts (Yoshizawa et al., 2004; Hjelmeland et 
al., 2005). Taken together, these findings and our 
results indicate that Msx2 is a negative regulator 
during osteoblast differentiation.
    To date, the detailed TNF-α signaling pathways 
involved in the inhibition of osteogenic differen-
tiation remain unclear. Although a study has shown 
that TNF-α inhibits BMP-induced osteoblast diffe-
rentiation through activation of JNK signaling 
(Mukai et al., 2007), no links were presented 
between JNK activation and a specific target gene. 
Here, we demonstrated that the activation of the 
NF-κB pathway is responsible for Msx2 induction 
triggered by TNF-α. These results were obtained 
by using both a chemical NF-κB inhibitor and 
dnIκBα over-expression. Previously, we have shown 
that cycloheximide does not affect TNF-α-induced 
MSX2 expression in human vascular smooth 
muscle cells (Lee et al., 2010), indicating that the 
signal cascades triggered by TNF-α directly induce 
Msx2 expression. Alternatively, the JNK/c-Jun 
pathway did not appear to be involved in the Msx2 
induction by TNF-α because Msx2 expression was 
not affected by JNK inhibition. This finding does 
not rule out the involvement of the JNK/c-Jun 
pathway in TNF-α-mediated osteogenic inhibition 
because ALP expression suppressed by TNF-α 
was partially rescued by treatment with a JNK 
inhibitor. Our preliminary data suggest that Smurf1 
appears to be the prime downstream target of JNK 
activation (data not shown), necessitating further 
studies.
    In this study, BMP2 enhanced TNF-α-induced 
Msx2 expression even though there was a certain 
degree of variation in the magnitude. A previous 
Figure 5. JNK activation is not involved in TNF-α-induced Msx2 expression. 
(A, C) C2C12 cells were treated with the indicated reagents for 5 min (A) or 
for 24 h (C) and then immunoblot analysis and RT-PCR were performed. 
JNK activation was confirmed using whole cell lysates whereas the Msx2 
protein level was examined using nuclear extracts. (B) SP600125 did not ex-
ert any cytotoxic effects at a concentration of 10 μM. Data represent the 
mean + SD of quadruplicates. *, P ＜ 0.01 (Student's t-test)
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report has shown that BMP2 rapidly induced the 
expression of homeodomain proteins such as 
Msx2 (2- to 3-fold) and Dlx5 (10- to14-fold) within 
24 h in C2C12 cells (Hassan et al., 2006). In our 
study, however, BMP2 increased slightly Msx2 
expression in some samples but not all (data not 
shown). It is not clear how BMP2 facilitated 
TNF-induced Msx2 expression but it is likely that in 
our culture system BMP2-activated signal was 
insufficient to induce Msx2 expression in itself but 
was able to heighten the Msx2 inducing signals by 
TNF. But further study is necessary to verify the 
signaling mechanism by which BMP2 enhance 
Msx2 expression.
    In summary, our study reveals that the inhibitory 
action of TNF-α on BMP2-regulated osteoblast 
differentiation requires Msx2 as a mediator and 
that the TNF-α-activated NF-κB pathway is 
responsible for Msx2 induction. Our results support 




Recombinant human TNF-α and BMP2 were purchased 
from R&D Systems (Minneapolis, MN). The easy-BLUETM 
and StarTaqTM reagents were ordered from iNtRON 
Biotechnology (Sungnam, Korea) and the AccuPower 
RT-PreMix was purchased from Bioneer (Daejeon, Korea). 
PCR primers were synthesized by TaKaRa Korea (Seoul, 
Korea). The Cell Counting Kit-8 (CCK-8) was purchased 
from Dojindo Molecular Technologies (Gaithersburg, MA). 
BAY-11-7082 and SP600125 were from Calbiochem 
(Gibbstown, NJ). The Alkaline Phosphatase staining kit, 
cycloheximide, and anti-Msx2 antibody were purchased 
from Sigma (St. Louis, MO). Anti-NF-κB p65, anti-lamin B, 
anti-actin antibodies, and goat anti-rabbit HRP-conjugated 
IgG were from Santa Cruz Biotechnology (Santa Cruz, 
CA). Anti-IκBα, anti-phospho-IκBα, anti-JNK, anti-phos-
pho-JNK, anti-c-Jun, anti-phospho-c-Jun, and anti-histone 
H3 antibodies were from Cell Signaling Technology 
(Danvers, MA). The Supex reagent for western blot 
analysis was ordered from Dyne-Bio (Sungnam, Korea). 
The NE-PER Nuclear and Cytoplasmic Extraction Reagent 
was obtained from PIERCE Biotechnology (Rockford, IL).
Cell culture, ALP staining, and transient transfection
C2C12 cells were cultured in DMEM supplemented with 
10% FBS. To induce osteogenic differentiation, sub-con-
fluent C2C12 cells were cultured in DMEM supplemented 
with 5% FBS and 100 ng/ml BMP2. Mouse calvarial 
osteoblasts (Runx2+/+ cells) were obtained from the frontal 
and parietal bones of neonatal ICR mice (Orient Bio Inc., 
Sungnam, Korea) as described previously (Kim et al., 
2002). Cells were maintained in DMEM supplemented with 
10% FBS. Runx2-/- cells, isolated from the primordium of 
calvarial tissue of Runx2-deficient mice (Lee et al., 2000), 
were maintained in α-MEM containing 10% FBS. For 
osteogenic differentiation, Runx2+/+ and Runx2-/- cells were 
cultured in α-MEM supplemented with 10% FBS, 100 
ng/ml BMP2, 10 mM β-glycerophosphate and 50 μg/ml 
ascorbic acid.
    To confirm the osteogenic differentiation, ALP staining 
was performed using the Alkaline Phosphatase staining kit 
according to the manufacturer’s instructions. 
    For the transient transfection of expression vectors for 
Msx2, Runx2 and dominant negative (dn) IκBα, 
LipofectAMINETM reagent was used.
RNA extraction and reverse transcription-PCR 
(RT-PCR)
To evaluate mRNA expression, semi-quantitative RT-PCR 
was performed in the range of linear amplification. Total 
RNA was isolated using easy-BLUETM RNA Extraction 
Reagents. cDNA was synthesized from total RNA using 
the AccuPowerTM RT-PreMix and subsequently subjected 
to PCR amplification using StarTaqTM polymerase. The 
PCR products were electrophoresed in a 1.2% agarose gel 
and visualized under UV light by ethidium bromide 
staining.
    Mouse genes and their primer sequences for PCR were 
as follows (in parentheses, the annealing temperature used 
for the PCR reaction and the product size are described; f 
and r represent the forward and reverse primers, respec-
tively): Msx2-f 5'-AACACAAGACCAACCGGAAG-3', Msx2-r 
5'-GCCGTATATGGATGCTGCTT-3' (58oC, 299 bps); Runx2-f 
5'-CCGCACGACAACCGCACCAT-3', Runx2-r 5'-CGCTC-
CGGCCCACAAATCTC-3' (56oC, 289 bps); Smad ubiquitin 
regulatory factor 1 (Smurf1)-f 5'-CTGGAGAACGAAGGAAC-
AGT-3', Smurf1-r 5'-CGCAGTTCACTGTTAAGG-3’ (56oC, 
364 bps); ALP-f 5'-AGGCAGGATTGACCACGG-3', ALP-r 
5'-TGTAGTTCTGCTCATGGA-3' (56oC, 439 bps); GAP-
DH-f 5'-TCACCATCTTCCAGGAGCG-3', GAPDH-r 5'-CT-
GCTTACCACCTTCTTGA-3' (56oC, 571 bps).
Cell cytotoxicity/proliferation assay
C2C12 cells were seeded at 1 × 103 cells/well in a 96-well 
plate. The following day, the adherent cells were fed with 
fresh differentiation medium containing 10 μM BAY-11-7082 
or 10 μM SP600125. At the end of the indicated incubation 
periods, the cells were washed with medium and further 
incubated for 1 h with the CCK8 reagent mixture. The 
absorbance was then measured at 490 nm. The values 
represent the means of quadruplicate measurements.
Western blot analysis
After the appropriate treatments, whole cell lysates or 
nuclear extracts were prepared for western blot analysis. 
For the whole cell lysate preparation, cells were lysed in 
buffer consisting of 10 mM Tris-Cl (pH 7.5), 150 mM NaCl, 
1 mM EDTA (pH 8.0), 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM sodium fluoride, 0.2 mM 
sodium orthovanadate, 1 mM PMSF, 1 μg/ml aprotinin, 1 
μM leupeptin, and 1 μM pepstatin. The lysates were then 
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sonicated briefly and centrifuged at 16,000 × g for 10 min, 
and the supernatants were used for immunoblot analysis. 
Nuclear extracts were prepared using NE-PER Nuclear 
and Cytoplasmic Extraction Reagents according to the 
manufacturer's instructions. Protein concentrations were 
determined using a modified Bradford method. Each 
sample containing equal amounts of protein was subjected 
to SDS-PAGE. The proteins separated in the gel were 
subsequently transferred onto a PVDF membrane. The 
membrane was blocked with 5% nonfat dry milk in 
Tris-buffered saline containing 0.1% Tween20, incubated 
with the indicated primary antibody, and subsequently 
incubated with HRP-conjugated secondary antibody.  
Immune complexes were visualized using the Supex 
reagent and luminescence was detected with a LAS1000 
(Fuji PhotoFilm; Tokyo, Japan).
Msx2 knockdown using small interfering (si) RNA 
Msx2 siRNA and control siRNA (ON-TARGETplus Non-tar-
geting siRNA #2 D-001210-02-05) were purchased from 
Dharmacon (Chicago, IL). Transfection into C2C12 cells 
was performed according to the manufacturer's instructions.
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